{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T09:45:41Z","timestamp":1724924741319},"reference-count":52,"publisher":"Hogrefe Publishing Group","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2019,1]]},"abstract":" Zusammenfassung. Schlaf ist ein komplexes Verhalten, das von verschiedenen Kerngebieten im Gehirn koordiniert wird. Diese neurochemischen Systeme modulieren die Wachheit und den Schlaf und k\u00f6nnen pharmakologisch beeinflusst werden. Die exzessive Tageschl\u00e4frigkeit (ETS) wird gew\u00f6hnlich mit dopaminergen Pharmaka behandelt, die in leichten F\u00e4llen von Koffein \u00fcber (Ar)Modafinil zu Amphetamin-Derivaten reichen. Trizyklische Antidepressiva und Melatonin-basierte Medikamente werden auch verwendet, aber in geringerem Masse. Zu den Arzneimitteln zur Schlaff\u00f6rderung geh\u00f6ren GABA-erge Medikamente wie Benzodiazepine und Z-Hypnotika sowie Histamin-H1-Rezeptor-Antagonisten. Exogenes Melatonin oder eine pharmakologische Kombination aus Melatonin-Rezeptor-Agonismus und 5-HT2C-Rezeptor-Antagonismus werden auch in weniger schweren F\u00e4llen verwendet. Als zuk\u00fcnftige schlaff\u00f6rdernde Medikamente werden zurzeit selektive und duale Orexin(Hypocretin)-Rezeptor-Antagonisten (DORA), aber auch Medikamente, die an spezifische 5-HT-Rezeptoren binden, untersucht. Die pharmakologische Behandlung ist jedoch nicht immer die prim\u00e4re Behandlungsmethode. Insomnie wird in erster Linie mit einer kognitiven Verhaltenstherapie behandelt, zur Behandlung von Schlafapnoe wird eine \u00dcberdruckbeatmung eingesetzt. <\/jats:p>","DOI":"10.1024\/1661-8157\/a003189","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T07:30:23Z","timestamp":1549438223000},"page":"131-138","source":"Crossref","is-referenced-by-count":4,"title":["Pharmakotherapie von Schlaf-Wach-St\u00f6rungen"],"prefix":"10.1024","volume":"108","author":[{"given":"Sebastian C.","family":"Holst","sequence":"first","affiliation":[{"name":"Copenhagen University Hospital, Rigshospitalet, Department of Neurology and Neurobiology Research Unit, Kopenhagen, D\u00e4nemark"},{"name":"Sleep and Health Z\u00fcrich (SHZ), Universit\u00e4t Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Werth","sequence":"additional","affiliation":[{"name":"Sleep and Health Z\u00fcrich (SHZ), Universit\u00e4t Z\u00fcrich"},{"name":"Klinik f\u00fcr Neurologie, Universit\u00e4tsspital Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Landolt","sequence":"additional","affiliation":[{"name":"Sleep and Health Z\u00fcrich (SHZ), Universit\u00e4t Z\u00fcrich"},{"name":"Institut f\u00fcr Pharmakologie und Toxikologie, Universit\u00e4t Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","reference":[{"key":"c1","doi-asserted-by":"crossref","unstructured":"Olesen J, Gustavsson A, Svensson M, Wittchen HU, J\u00f6nsson B: The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19: 155\u2013162.","DOI":"10.1111\/j.1468-1331.2011.03590.x"},{"key":"c2","doi-asserted-by":"crossref","unstructured":"Morin CM, Benca R: Chronic insomnia. Lancet 2012; 379: 1129\u20131141.","DOI":"10.1016\/S0140-6736(11)60750-2"},{"key":"c3","doi-asserted-by":"crossref","unstructured":"Riemann D, Baglioni C, Bassetti C, et al.: European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017; 26: 675\u2013700.","DOI":"10.1111\/jsr.12594"},{"key":"c4","doi-asserted-by":"crossref","unstructured":"Dell\u2019osso B, Lader M: Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 2013; 28: 7\u201320.","DOI":"10.1016\/j.eurpsy.2011.11.003"},{"key":"c5","doi-asserted-by":"crossref","unstructured":"Dresler M, Spoormaker VI, Beitinger P, et al.: Neuroscience-driven discovery and development of sleep therapeutics. Pharmacol Ther 2014; 141: 300\u2013334.","DOI":"10.1016\/j.pharmthera.2013.10.012"},{"key":"c6","doi-asserted-by":"crossref","unstructured":"Riemann D, Perlis ML: The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med Rev 2009; 13: 205\u2013214.","DOI":"10.1016\/j.smrv.2008.06.001"},{"key":"c7","doi-asserted-by":"crossref","unstructured":"Rudolph U, M\u00f6hler H: GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol 2006; 6: 18\u201323.","DOI":"10.1016\/j.coph.2005.10.003"},{"key":"c8","doi-asserted-by":"crossref","unstructured":"Riemann D, Nissen C: Substance-induced sleep disorders and abuse of hypnotics. Bundesgesundheitsblatt Gesundheitsforsch Gesundheitsschutz 2011; 54: 1325\u20131331.","DOI":"10.1007\/s00103-011-1374-2"},{"key":"c9","doi-asserted-by":"crossref","unstructured":"Krystal AD, Richelson E, Roth T: Review of the histamine system and the clinical effects of H1 antagonists: Basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev 2013; 17: 263\u2013272.","DOI":"10.1016\/j.smrv.2012.08.001"},{"key":"c10","doi-asserted-by":"crossref","unstructured":"Goforth HW: Low-dose doxepin for the treatment of insomnia: emerging data. Expert Opin Pharmacother 2009; 10: 1649\u20131655.","DOI":"10.1517\/14656560903005587"},{"key":"c11","doi-asserted-by":"crossref","unstructured":"Schittecatte M, Dumont F, Machowski R, Cornil C, Lavergne F, Wilmotte J: Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002; 46: 197\u2013201.","DOI":"10.1159\/000067812"},{"key":"c12","doi-asserted-by":"crossref","unstructured":"Wilson S, Argyropoulos S: Antidepressants and sleep: A qualitative review of the literature. Drugs 2005; 65: 927\u2013947.","DOI":"10.2165\/00003495-200565070-00003"},{"key":"c13","doi-asserted-by":"crossref","unstructured":"Zisapel N: Current phase II investigational therapies for insomnia. Expert Opin Investig Drugs 2015; 24: 401\u2013411.","DOI":"10.1517\/13543784.2015.987340"},{"key":"c14","doi-asserted-by":"crossref","unstructured":"Patel KV, Aspesi AV, Evoy KE: Suvorexant: A dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia. Ann Pharmacother 2015; 49: 477\u2013483.","DOI":"10.1177\/1060028015570467"},{"key":"c15","doi-asserted-by":"crossref","unstructured":"Hoyer D, Jacobson LH: Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides 2013; 47: 477\u2013488.","DOI":"10.1016\/j.npep.2013.10.009"},{"key":"c16","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-San-Mart\u00edn MI, Masa-Font R, Palacios-Soler L, Sancho-G\u00f3mez P, Calb\u00f3-Caldentey C, Flores-Mateo G: Effectiveness of valerian on insomnia: A meta-analysis of randomized placebo-controlled trials. Sleep Med 2010; 11: 505\u2013511.","DOI":"10.1016\/j.sleep.2009.12.009"},{"key":"c17","doi-asserted-by":"crossref","unstructured":"Kumar S, Sagili H: Etiopathogebesis and neurobiology of narcolepsy: A review. J Clin Diagnostic Res 2014; 8: 190\u2013195.","DOI":"10.7860\/JCDR\/2014\/7295.4057"},{"key":"c18","doi-asserted-by":"crossref","unstructured":"Banerjee D, Vitiello MV, Grunstein RR: Pharmacotherapy for excessive daytime sleepiness. Sleep Med Rev 2004; 8: 339\u2013354.","DOI":"10.1016\/j.smrv.2004.03.002"},{"key":"c19","doi-asserted-by":"crossref","unstructured":"Holst SC, Landolt HP: Sleep homeostasis, metabolism, and adenosine. Curr Sleep Med Reports 2015; 1: 27\u201337.","DOI":"10.1007\/s40675-014-0007-3"},{"key":"c20","doi-asserted-by":"crossref","unstructured":"Clark I, Landolt HP. Coffee, caffeine, and sleep: A systematic review of epidemiological studies and randomized controlled trials. Sleep Med Rev 2017; 31: 70\u201378.","DOI":"10.1016\/j.smrv.2016.01.006"},{"key":"c21","doi-asserted-by":"crossref","unstructured":"Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R: Association of coffee drinking with total and cause-specific mortality. N Engl J Med 2012; 366: 1891\u20131904.","DOI":"10.1056\/NEJMoa1112010"},{"key":"c22","doi-asserted-by":"crossref","unstructured":"Loftfield E, Cornelis MC, Caporaso N, Yu K, Sinha R, Freedman N: Association of coffee drinking with mortality by genetic variation in caffeine metabolism: Findings from the UK Biobank. JAMA Intern Med 2018; 178: 1086\u20131097.","DOI":"10.1001\/jamainternmed.2018.2425"},{"key":"c23","doi-asserted-by":"crossref","unstructured":"Mignot EJM: A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics 2012; 9: 739\u2013752.","DOI":"10.1007\/s13311-012-0150-9"},{"key":"c24","doi-asserted-by":"crossref","unstructured":"Billiard M, Bassetti C, Dauvilliers Y, et al.: EFNS guidelines on management of narcolepsy. Eur J Neurol 2006; 13: 1035\u20131048.","DOI":"10.1111\/j.1468-1331.2006.01473.x"},{"key":"c25","doi-asserted-by":"crossref","unstructured":"Volkow ND, Fowler JS, Logan J, et al.: Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications. JAMA 2009; 301: 1148\u20131154.","DOI":"10.1001\/jama.2009.351"},{"key":"c26","doi-asserted-by":"crossref","unstructured":"Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM: Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21: 1787\u20131794.","DOI":"10.1523\/JNEUROSCI.21-05-01787.2001"},{"key":"c27","doi-asserted-by":"crossref","unstructured":"Darwish M, Kirby M, Hellriegel ET, Robertson P: Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: Analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig 2009; 29: 613\u2013623.","DOI":"10.2165\/11315280-000000000-00000"},{"key":"c28","doi-asserted-by":"crossref","unstructured":"Mitler MM, Shafor R, Hajdukovich R, Timms RM, Browman CP: Treatment of narcolepsy: Objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986; 9: 260\u2013264.","DOI":"10.1093\/sleep\/9.1.260"},{"key":"c29","doi-asserted-by":"crossref","unstructured":"Nittur N, Konofal E, Dauvilliers Y, et al.: Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: A long-term chart review. Sleep Med 2013; 14: 30\u201336.","DOI":"10.1016\/j.sleep.2012.07.008"},{"key":"c30","doi-asserted-by":"crossref","unstructured":"Thorpy MJ, Dauvilliers Y: Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med 2015; 16: 9\u201318.","DOI":"10.1016\/j.sleep.2014.10.002"},{"key":"c31","doi-asserted-by":"crossref","unstructured":"Stocking EM, Letavic M: Histamine H3 antagonists as wake-promoting and pro-cognitive agents. Curr Top Med Chem 2008; 8: 988\u20131002.","DOI":"10.2174\/156802608784936728"},{"key":"c32","doi-asserted-by":"crossref","unstructured":"Lin J-S, Sergeeva OA, Haas HL: Histamine H3 receptors and sleep-wake regulation. J Pharmacol Exp Ther 2011; 336: 17\u201323.","DOI":"10.1124\/jpet.110.170134"},{"key":"c33","doi-asserted-by":"crossref","unstructured":"Holst SC, Valomon A, Landolt HP: Sleep pharmacogenetics: personalized sleep-wake therapy. Annu Rev Pharmacol Toxicol 2016; 56: 577\u2013603.","DOI":"10.1146\/annurev-pharmtox-010715-103801"},{"key":"c34","doi-asserted-by":"crossref","unstructured":"Houghton WC, Scammell TE, Thorpy M: Pharmacotherapy for cataplexy. Sleep Med Rev 2004; 8: 355\u2013366.","DOI":"10.1016\/j.smrv.2004.01.004"},{"key":"c35","doi-asserted-by":"crossref","unstructured":"Dhillon S, Clarke M: Tasimelteon: first global approval. Drugs 2014; 74: 505\u2013511.","DOI":"10.1007\/s40265-014-0200-1"},{"key":"c36","doi-asserted-by":"crossref","unstructured":"De Berardis\n D, Fornaro M, Serroni N, et al.: Agomelatine beyond borders: Current evidences of its efficacy in disorders other than major depression. Int J Mol Sci 2015; 16: 1111\u20131130.","DOI":"10.3390\/ijms16011111"},{"key":"c37","doi-asserted-by":"crossref","unstructured":"Videnovic A, Noble C, Reid KJ, et al.: Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol 2014; 71: 463\u2013469.","DOI":"10.1001\/jamaneurol.2013.6239"},{"key":"c38","doi-asserted-by":"crossref","unstructured":"Zanigni S, Calandra-Buonaura G, Grimaldi D, Cortelli P: REM behaviour disorder and neurodegenerative diseases. Sleep Med 2011; 12; S54\u201358.","DOI":"10.1016\/j.sleep.2011.10.012"},{"key":"c39","doi-asserted-by":"crossref","unstructured":"McGrane IR, Leung JG, St. Louis\n EK, Boeve BF: Melatonin therapy for REM sleep behavior disorder: A critical review of evidence. Sleep Med 2015; 16: 19\u201326.","DOI":"10.1016\/j.sleep.2014.09.011"},{"key":"c40","doi-asserted-by":"crossref","unstructured":"Trenkwalder C, Paulus W: Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 2010; 6: 337\u2013346.","DOI":"10.1038\/nrneurol.2010.55"},{"key":"c41","doi-asserted-by":"crossref","unstructured":"Trenkwalder C, Bene\u0161 H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: A double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 2013; 12: 1141\u20131150.","DOI":"10.1016\/S1474-4422(13)70239-4"},{"key":"c42","doi-asserted-by":"crossref","unstructured":"Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, G\u00f6der R, Baier PC: The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res 2014; 262: 8\u201313.","DOI":"10.1016\/j.bbr.2013.12.045"},{"key":"c43","doi-asserted-by":"crossref","unstructured":"Partin KM: AMPA receptor potentiators: From drug design to cognitive enhancement. Curr Opin Pharmacol 2015; 20: 46\u201353.","DOI":"10.1016\/j.coph.2014.11.002"},{"key":"c44","doi-asserted-by":"crossref","unstructured":"Porrino LJ, Daunais JB, Rogers GA, Hampson RE, Deadwyler SA: Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol 2005; 3: 1639\u20131652.","DOI":"10.1371\/journal.pbio.0030299"},{"key":"c45","doi-asserted-by":"crossref","unstructured":"Boyle J, Stanley N, James LM, et al.: Acute sleep deprivation: The effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep. J Psychopharmacol 2012; 26: 1047\u20131057.","DOI":"10.1177\/0269881111405353"},{"key":"c46","doi-asserted-by":"crossref","unstructured":"Baladi MG, Forster MJ, Gatch MB, et al.: Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2018; 366: 367\u2013376.","DOI":"10.1124\/jpet.118.248120"},{"key":"c47","doi-asserted-by":"crossref","unstructured":"Monti JM: Serotonin control of sleep-wake behavior. Sleep Med Rev 2011; 15: 269\u2013281.","DOI":"10.1016\/j.smrv.2010.11.003"},{"key":"c48","doi-asserted-by":"crossref","unstructured":"Landolt HP, Meier V, Burgess HJ, et al.: Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 1999; 21: 455\u2013466.","DOI":"10.1016\/S0893-133X(99)00052-4"},{"key":"c49","doi-asserted-by":"crossref","unstructured":"Landolt HP, Wehrle R: Antagonism of serotonergic 5-HT2A\/2C receptors: Mutual improvement of sleep, cognition and mood? Eur J Neurosci 2009; 29: 1795\u20131809.","DOI":"10.1111\/j.1460-9568.2009.06718.x"},{"key":"c50","doi-asserted-by":"crossref","unstructured":"Spadoni G, Bedini A, Rivara S, Mor M: Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther 2011; 17: 733\u2013741.","DOI":"10.1111\/j.1755-5949.2010.00197.x"},{"key":"c51","doi-asserted-by":"crossref","unstructured":"Carocci A, Catalano A, Sinicropi MS: Melatonergic drugs in development. Clin Pharmacol Adv Appl 2014; 6: 127\u2013137.","DOI":"10.2147\/CPAA.S36600"},{"key":"c52","doi-asserted-by":"crossref","unstructured":"Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A: The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005; 66: 384\u2013390.","DOI":"10.4088\/JCP.v66n0316"}],"container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a003189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T19:36:46Z","timestamp":1615923406000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a003189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1024\/1661-8157\/a003189"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a003189","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}